First-of-its-kind quality improvement initiative, Project EVEREST, is backed by Daiichi Sankyo, Genentech, and AstraZeneca.
Novellia, Inc., the AI health data platform trusted by leading biopharma companies to uncover hidden insights in real-world patient data, announced the launch of Project EVEREST—a groundbreaking, cross-industry initiative designed to improve adherence to clinical guidelines in the treatment of early and metastatic breast cancer. Project EVEREST unites leading researchers, clinicians, and biopharmaceutical companies—including Daiichi Sankyo, Genentech, and AstraZeneca—to identify and address the barriers preventing consistent, evidence-based cancer care across health care settings.
As the first AI-enabled, patient-permissioned longitudinal registry focused on real-world treatment adherence in breast cancer, Project EVEREST brings together a cross-industry coalition to set a new standard for quality improvement research.
Health Technology Insights: BioIVT and Handok Biotech Partner to Boost Innovation in South Korea
Leveraging Novellia’s proprietary AI platform, Project EVEREST will create a robust, longitudinal patient registry by unifying complex medical histories across NCI-designated cancer centers, lab centers, and regional health systems. Researchers from the University of Alabama at Birmingham (UAB) will analyze these unified datasets to uncover patterns in care delivery, identify actionable gaps in the application of current breast cancer treatment guidelines, and deliver targeted recommendations for improving treatment consistency and patient outcomes.
“The key question we aim to answer is what systemic and clinical factors are preventing patients from receiving the most current, evidence-based care for breast cancer,” said Dr. Humaira Sarfraz, Assistant Professor of Medicine and clinician-educator in the Division of Hematology and Oncology at the UAB Medical Center. “The field of oncology is moving at an unprecedented rate, and next-generation, AI-enabled data platforms open up possibilities for us to drive better outcomes for patients by examining real-world data along with patient medical histories and pinpoint where care may fall short in ways that were previously impossible or time prohibitive.”
Health Technology Insights: Hydreight Launches Personalized Genetic Testing on VSDHOne
“When biopharma teams face questions others can’t answer, they turn to Novellia for our unique ability to build full, sequential patient stories that reveal hidden insights traditional data providers aren’t equipped to find. Project EVEREST builds on our reputation as the only data partner that goes deep enough to solve the toughest challenges in healthcare,” said Shashi Shankar, CEO and co-founder of Novellia. “In the past, building these sorts of longitudinal datasets would have cost tens of millions of dollars and required several months of manual data processing by teams of clinical abstractors. By using AI to autonomously unify fragmented health histories and surface critical blind spots missed by traditional real-world data solutions, we’re closing the gap between data and decisions. Project EVEREST brings together biopharma leaders, top researchers, and our AI-enabled platform to deliver a scalable model for evidence-based care improvement in breast cancer—and a roadmap for addressing care variation across other complex diseases.”
The program will enroll early and metastatic breast cancer patients, including those with HER2+ and HR+/HER2- subtypes. Over a 24-month period, researchers will aggregate and analyze hundreds of thousands of retrospective and prospective patient records to identify trends and deviations from established treatment guidelines. In Phase 2, researchers will then deliver tailored, evidence-based interventions to support health systems and community oncologists in optimizing care delivery, advancing the standard of care through measurable, real-world impact and improved patient outcomes.
Health Technology Insights: Life365 Appoints Healthcare Veteran Jay Roberts as Chief Development Officer
To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com
Source – PR Newswire
